Bladder cancer risk in users of selected drugs for cardiovascular disease prevention

Valentina Guercio, Federica Turati, Cristina Bosetti, Jerry Polesel, Diego Serraino, Maurizio Montella, Massimo Libra, Antonio Galfano, Carlo La Vecchia, Alessandra Tavani

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins, and calcium channel blockers (CCBs). We analyzed data from a multicentric case-control study carried out in Italy between 2003 and 2014, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) of bladder cancer and corresponding 95% confidence intervals (CIs) were estimated using unconditional multiple logistic regression models. The ORs for bladder cancer were 1.21 (95% CI: 0.87-1.68) for regular use of aspirin, 0.72 (95% CI: 0.54-0.97) for use of any CCBs, and 1.32 (95% CI: 0.87-1.99) for use of any statins. A slight inverse association was found with duration of use of CCBs, whereas no consistent association was found with duration of use, age at first use, and frequency for aspirin and statin use, or with indication of use for aspirin (as an analgesic or, for CVD prevention). No significant association was found for various combinations of drugs or for all drugs combined (OR=1.23, 95% CI: 0.31-4.85). Our data indicate the lack of a relevant association between the use of selected drugs for CVD prevention and bladder cancer risk, although suggest a potential favorable role for CCBs.

Original languageEnglish
JournalEuropean Journal of Cancer Prevention
DOIs
Publication statusE-pub ahead of print - Dec 26 2017

Fingerprint

Drug Users
Urinary Bladder Neoplasms
Calcium Channel Blockers
Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Aspirin
Confidence Intervals
Odds Ratio
Logistic Models
Pharmaceutical Preparations
Drug Combinations
Italy
Analgesics
Case-Control Studies

Cite this

Bladder cancer risk in users of selected drugs for cardiovascular disease prevention. / Guercio, Valentina; Turati, Federica; Bosetti, Cristina; Polesel, Jerry; Serraino, Diego; Montella, Maurizio; Libra, Massimo; Galfano, Antonio; La Vecchia, Carlo; Tavani, Alessandra.

In: European Journal of Cancer Prevention, 26.12.2017.

Research output: Contribution to journalArticle

@article{96b3385438aa43bda028f83581024180,
title = "Bladder cancer risk in users of selected drugs for cardiovascular disease prevention",
abstract = "The aim of this study was to investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins, and calcium channel blockers (CCBs). We analyzed data from a multicentric case-control study carried out in Italy between 2003 and 2014, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) of bladder cancer and corresponding 95{\%} confidence intervals (CIs) were estimated using unconditional multiple logistic regression models. The ORs for bladder cancer were 1.21 (95{\%} CI: 0.87-1.68) for regular use of aspirin, 0.72 (95{\%} CI: 0.54-0.97) for use of any CCBs, and 1.32 (95{\%} CI: 0.87-1.99) for use of any statins. A slight inverse association was found with duration of use of CCBs, whereas no consistent association was found with duration of use, age at first use, and frequency for aspirin and statin use, or with indication of use for aspirin (as an analgesic or, for CVD prevention). No significant association was found for various combinations of drugs or for all drugs combined (OR=1.23, 95{\%} CI: 0.31-4.85). Our data indicate the lack of a relevant association between the use of selected drugs for CVD prevention and bladder cancer risk, although suggest a potential favorable role for CCBs.",
author = "Valentina Guercio and Federica Turati and Cristina Bosetti and Jerry Polesel and Diego Serraino and Maurizio Montella and Massimo Libra and Antonio Galfano and {La Vecchia}, Carlo and Alessandra Tavani",
year = "2017",
month = "12",
day = "26",
doi = "10.1097/CEJ.0000000000000419",
language = "English",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Bladder cancer risk in users of selected drugs for cardiovascular disease prevention

AU - Guercio, Valentina

AU - Turati, Federica

AU - Bosetti, Cristina

AU - Polesel, Jerry

AU - Serraino, Diego

AU - Montella, Maurizio

AU - Libra, Massimo

AU - Galfano, Antonio

AU - La Vecchia, Carlo

AU - Tavani, Alessandra

PY - 2017/12/26

Y1 - 2017/12/26

N2 - The aim of this study was to investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins, and calcium channel blockers (CCBs). We analyzed data from a multicentric case-control study carried out in Italy between 2003 and 2014, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) of bladder cancer and corresponding 95% confidence intervals (CIs) were estimated using unconditional multiple logistic regression models. The ORs for bladder cancer were 1.21 (95% CI: 0.87-1.68) for regular use of aspirin, 0.72 (95% CI: 0.54-0.97) for use of any CCBs, and 1.32 (95% CI: 0.87-1.99) for use of any statins. A slight inverse association was found with duration of use of CCBs, whereas no consistent association was found with duration of use, age at first use, and frequency for aspirin and statin use, or with indication of use for aspirin (as an analgesic or, for CVD prevention). No significant association was found for various combinations of drugs or for all drugs combined (OR=1.23, 95% CI: 0.31-4.85). Our data indicate the lack of a relevant association between the use of selected drugs for CVD prevention and bladder cancer risk, although suggest a potential favorable role for CCBs.

AB - The aim of this study was to investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins, and calcium channel blockers (CCBs). We analyzed data from a multicentric case-control study carried out in Italy between 2003 and 2014, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) of bladder cancer and corresponding 95% confidence intervals (CIs) were estimated using unconditional multiple logistic regression models. The ORs for bladder cancer were 1.21 (95% CI: 0.87-1.68) for regular use of aspirin, 0.72 (95% CI: 0.54-0.97) for use of any CCBs, and 1.32 (95% CI: 0.87-1.99) for use of any statins. A slight inverse association was found with duration of use of CCBs, whereas no consistent association was found with duration of use, age at first use, and frequency for aspirin and statin use, or with indication of use for aspirin (as an analgesic or, for CVD prevention). No significant association was found for various combinations of drugs or for all drugs combined (OR=1.23, 95% CI: 0.31-4.85). Our data indicate the lack of a relevant association between the use of selected drugs for CVD prevention and bladder cancer risk, although suggest a potential favorable role for CCBs.

U2 - 10.1097/CEJ.0000000000000419

DO - 10.1097/CEJ.0000000000000419

M3 - Article

C2 - 29280915

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

ER -